PE20020616A1 - Compuestos de piperidina como antagonistas del receptor ccr-3 - Google Patents

Compuestos de piperidina como antagonistas del receptor ccr-3

Info

Publication number
PE20020616A1
PE20020616A1 PE2001000683A PE2001000683A PE20020616A1 PE 20020616 A1 PE20020616 A1 PE 20020616A1 PE 2001000683 A PE2001000683 A PE 2001000683A PE 2001000683 A PE2001000683 A PE 2001000683A PE 20020616 A1 PE20020616 A1 PE 20020616A1
Authority
PE
Peru
Prior art keywords
alkyl
ccr
phenyl
halogen
receptor
Prior art date
Application number
PE2001000683A
Other languages
English (en)
Inventor
Grand Darren Mark Le
Gurdip Bhalay
Trevor John Howe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0017174A external-priority patent/GB0017174D0/en
Priority claimed from GB0023326A external-priority patent/GB0023326D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20020616A1 publication Critical patent/PE20020616A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DE PIPERIDINA DE FORMULA I DONDE: Ar1 ES FENILO SUSTITUIDO POR HALOGENO; Ar2 ES FENILO, NAFTILO OPCIONALMENTE SUSTITUIDO POR HALOGENO, CIANO, HIDROXILO, NITRO, ALQUILO C1-C8, HALOALQUILO C1-C8, ALCOXILO C1-C8, ALCOXICARBONILO C1-C8; R1 ES H, ALQUILO C1-C8 OPCIONALMENTE SUSTITUIDO POR OH, ALCOXILO C1-C8, ACILOXILO, NR2R3, HALOGENO, CARBOXILO, ALCOXI-CARBONILO C1-C8, CONR4R5; R2 Y R3 SON H, ALQUILO C1-C8; R2 ES H; R3 ES ACILO, SO2R6; R2 Y R3 JUNTO CON N FORMAN UN HETEROCICLO DE 5-6 MIEMBROS; R4 Y R5 SON H, ALQUILO C1-C8 O JUNTO CON N FORMAN UN HETEROCICLO DE 5-6 MIEMBROS; R6 ES ALQUILO C1-C8, HALOALQUILO C1-C8, FENILO; n ES 1-4; CUANDO Ar1 ES p-CLOROFENILO; R1 ES H; Ar2 NO ES FENILO O p-NITROFENILO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I SE PUEDE UTILIZAR JUNTO CON ANTIINFLAMATORIO, BRONCODILATADOR, ANTIHISTAMINA Y ES ANTAGONISTA DEL RECEPTOR CCR-3 E INHIBE LA INFILTRACION Y ACTIVACION DE CELULAS INFLAMATORIAS (EOSINOFILOS) E INHIBE LA RESPUESTA ALERGICA CCR-3
PE2001000683A 2000-07-12 2001-07-10 Compuestos de piperidina como antagonistas del receptor ccr-3 PE20020616A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0017174A GB0017174D0 (en) 2000-07-12 2000-07-12 Organic compounds
GB0023326A GB0023326D0 (en) 2000-09-22 2000-09-22 Organic compounds

Publications (1)

Publication Number Publication Date
PE20020616A1 true PE20020616A1 (es) 2002-08-02

Family

ID=26244644

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000683A PE20020616A1 (es) 2000-07-12 2001-07-10 Compuestos de piperidina como antagonistas del receptor ccr-3

Country Status (25)

Country Link
US (1) US6670379B2 (es)
EP (1) EP1303488B1 (es)
JP (1) JP2004502756A (es)
KR (1) KR20030036603A (es)
CN (1) CN1184204C (es)
AR (1) AR031597A1 (es)
AT (1) ATE447553T1 (es)
AU (2) AU2001281972B2 (es)
BR (1) BR0112456A (es)
CA (1) CA2412941C (es)
CZ (1) CZ200375A3 (es)
DE (1) DE60140366D1 (es)
ES (1) ES2334886T3 (es)
HU (1) HUP0301341A2 (es)
IL (1) IL153661A0 (es)
MX (1) MXPA02012848A (es)
MY (1) MY126139A (es)
NO (1) NO324760B1 (es)
NZ (1) NZ523414A (es)
PE (1) PE20020616A1 (es)
PL (1) PL358673A1 (es)
PT (1) PT1303488E (es)
SK (1) SK272003A3 (es)
TW (1) TWI227231B (es)
WO (1) WO2002004420A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952147A1 (de) * 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU2001295601A1 (en) * 2000-10-09 2002-04-22 Novartis Pharma Gmbh N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists
GB0114699D0 (en) * 2001-06-15 2001-08-08 Novartis Ag Organic compounds
ES2452691T5 (es) 2003-09-16 2022-09-14 Covis Pharma Gmbh Uso de ciclesonida para el tratamiento de enfermedades respiratorias
JP6473133B2 (ja) * 2013-03-15 2019-02-20 アラクセス ファーマ エルエルシー Ｋｒａｓｇ１２ｃの共有結合性阻害剤
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CN107849022A (zh) 2015-04-10 2018-03-27 亚瑞克西斯制药公司 取代的喹唑啉化合物和其使用方法
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CN110036010A (zh) 2016-09-29 2019-07-19 亚瑞克西斯制药公司 Kras g12c突变蛋白的抑制剂
CN110312711A (zh) 2016-10-07 2019-10-08 亚瑞克西斯制药公司 作为ras抑制剂的杂环化合物及其使用方法
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
TW201906832A (zh) 2017-05-25 2019-02-16 美商亞瑞克西斯製藥公司 用於癌症治療之化合物及其使用方法
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
EP3630747A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Quinazoline derivatives as modulators of mutant kras, hras or nras

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8576098A (en) * 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6339087B1 (en) 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
CN1163484C (zh) 1998-11-17 2004-08-25 霍夫曼-拉罗奇有限公司 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
CA2348923A1 (en) * 1998-12-18 2000-06-22 Dean A. Wacker N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2361366A1 (en) * 1999-03-26 2000-10-05 Nicholas Kindon Novel compounds

Also Published As

Publication number Publication date
KR20030036603A (ko) 2003-05-09
ES2334886T3 (es) 2010-03-17
DE60140366D1 (de) 2009-12-17
AR031597A1 (es) 2003-09-24
US6670379B2 (en) 2003-12-30
TWI227231B (en) 2005-02-01
CN1184204C (zh) 2005-01-12
US20030176460A1 (en) 2003-09-18
NO20030135L (no) 2003-02-19
BR0112456A (pt) 2003-07-22
EP1303488A1 (en) 2003-04-23
CN1441780A (zh) 2003-09-10
JP2004502756A (ja) 2004-01-29
PL358673A1 (en) 2004-08-09
CA2412941C (en) 2011-01-04
HUP0301341A2 (hu) 2003-08-28
ATE447553T1 (de) 2009-11-15
CZ200375A3 (cs) 2003-04-16
AU8197201A (en) 2002-01-21
SK272003A3 (en) 2003-07-01
EP1303488B1 (en) 2009-11-04
MXPA02012848A (es) 2003-05-15
NO20030135D0 (no) 2003-01-10
WO2002004420A1 (en) 2002-01-17
NO324760B1 (no) 2007-12-10
NZ523414A (en) 2004-07-30
PT1303488E (pt) 2010-01-19
IL153661A0 (en) 2003-07-06
AU2001281972B2 (en) 2004-06-03
MY126139A (en) 2006-09-29
CA2412941A1 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
PE20020616A1 (es) Compuestos de piperidina como antagonistas del receptor ccr-3
PE20020580A1 (es) Aminotiazoles como antagonistas del receptor de adenosina
PE20020485A1 (es) Derivados de quinolina y quinazolina como antagonistas del neuropeptido y
ECSP066329A (es) Derivados de pentanol heterocíclicamente sustituidos, procedimiento para su preparación y su uso como anti-inflamatorios
EA200300619A1 (ru) Серотонинергические средства
PE20020508A1 (es) DERIVADOS DE PIRIDINA COMO INHIBIDORES DE LA ACTIVIDAD DE LA QUINASA IkB ß
PE20060483A1 (es) Compuestos heterociclicos como antagonistas de nk1
PE20100737A1 (es) Nuevos compuestos
PE20061093A1 (es) Piperazinas sustituidas con heterociclos con actividad antagonista de cxcr3
AR053790A1 (es) Acidos biariloximetilarencarboxilicos. procesos de obtencion y composiciones farmaceuticas.
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
PE20020532A1 (es) Derivados de naftaleno como agonistas del receptor canabinoide
PE20040512A1 (es) Compuesto de pirazol-pirimidina anilina
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
HUP0201659A2 (hu) Kristályos benzimidazol-vegyület
PE20020506A1 (es) Derivados de pirazol fusionados como inhibidores de la proteina cinasa
ES8700252A1 (es) Procedimiento para preparar nuevos compuestos indolicos
PE20050951A1 (es) Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas
PE20030702A1 (es) Inhibidores de pde9 para tratamiento de transtornos cardiovasculares
TNSN05014A1 (fr) Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1
MA28432B1 (fr) Antagonistes du recepteur de la chimiokine
EA200201119A1 (ru) Лиганды меланокортиновых рецепторов
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
DE60214990D1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
PE20041078A1 (es) Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh)

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed